Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk's flagship products, Ozempic and Wegovy, are dominating the diabetes and obesity markets. Sales and operating profit growth are over 30%, so the company can double down on manufacturing and ratchet up supply capacity.

The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100

Novo Nordisk wants to buy more companies with drugs in early- to mid-stages of development through "bolt-on" deals of up to a few billion dollars, CEO Lars Fruergaard Jorgensen told Reuters on Friday.

Drugmaker Novo Nordisk seeks obesity, diabetes 'bolt-on' deals

Europe's largest pharma company, Novo Nordisk (NYSE:NVO), has unveiled plans for a significant investment of more than $6 billion to cater to the increasing demand for its Wegovy weight-loss treatment and other pharmaceutical products. The company will focus on expanding its Kalundborg facility in Denmark, enhancing capabilities throughout its value chain.

Novo Nordisk unveils $6bn investment plans

Novo Nordisk, the Danish pharmaceutical giant that makes the blockbuster Wegovy obesity drug, said it will invest over $6 billion to boost production capacity.

Wegovy Maker Novo Nordisk to Spend $6 Billion Boosting Production Capacity

Novo Nordisk said on Friday it will invest more than 42 billion Danish crowns ($6 billion) from 2023 onwards to expand its manufacturing facilities in Denmark for the current and future product portfolio within serious chronic diseases.

Novo Nordisk to invest $6 bln in Denmark expansions

Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg, Denmark, for the current and future product portfolio within serious chronic diseases.

Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark

Novo Nordisk's weight-loss drug Wegovy is relatively cheap with insurance. That means its addressable market is less constrained by affordability concerns.

People Are Paying $25 for Wegovy, and It's Going to Keep Making Novo Nordisk Billions

Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

Novo Nordisk to discontinue Levemir insulin in U.S. market

Arista Networks

Core Molding Technologies

CrowdStrike

Goosehead Insurance

Hawkins

Limbach Holdings

Dorian LPG

Stride

MINISO Group Holding

Qualys

Sterling Construction

Earnings growth is key to a winning stock. These stocks make the grade with several of them setting up in bases.

These Top Stocks Boast The Highest IBD Ratings

TEL AVIV, Israel , Nov. 7, 2023 /PRNewswire/ -- The Tel Aviv Stock Exchange Ltd (TASE: TASE) is pleased to announce the receipt, on Nov 02, 2023, of a notification from Novo Holdings A/S (hereafter: "the Interested Party"), a foreign company registered in Denmark, informing the Company that it is now an interested party in the Company, following the purchase in an OTC transaction of 4,312,024 shares for a consideration of NIS 17.3 per share. Subsequent to the aforesaid purchase, the Interested Party holds 7,785,515 shares of the Company, representing approximately 8.42% of the Company's issued share capital and the voting rights therein.

Novo Holdings A/S, a subsidiary of Novo Nordisk Foundation, becomes interested party in the Tel Aviv Stock Exchange (TASE), holding 8.42% shares

Danish drugmaker Novo Nordisk said on Tuesday it will present new cardiometabolic disease data, including results from its SELECT trial, at the annual American Heart Association Scientific Sessions from Nov. 11-13.

Novo Nordisk to present new cardiometabolic disease data mid-November

Two analysts separately raised their price targets on the shares. This provides even more bullish momentum for the Wegovy and Ozempic maker's stock.

Why Novo Nordisk Stock Trounced the Market Today

Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programm – Today, Novo Nordisk A/S has entered into an agreement to purchase 7,012,500 B shares of DKK 0.10 at a value of DKK 4,886 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S' 2023 share repurchase programme of up to a total of DKK 30 billion to be executed during a 12-month period beginning 1 February 2023. The transaction price is DKK 696.76 per share and has been calculated as the three-day volume weighted average market price from 2 November 2023 to 6 November 2023 in the open window following the announcement of Novo Nordisk A/S' quarterly financial results.

Novo Nordisk A/S purchases B shares worth DKK 4,886 million from Novo Holdings A/S under the 2023 share repurchase programme

Eli Lilly

The anti-obesity market could become a $100 billion industry by 2030, Goldman Sachs predicts. The field is "still in its early stages" but may have reached an inflection point, the bank said.

Ozempic and other weight-loss drugs will power the anti-obesity market to 16-fold gains by 2030, Goldman Sachs says

An analyst's price target bump was overshadowed by an insider's stock sale. Both were relatively small-scale events.

Why Novo Nordisk Stock Flopped on Friday

Novo Nordisk (NYSE:NVO) remains firmly in favour with analysts at Barclays ahead of the latest trial data for diabetes drug Wegovy that is due next week. It was the “stunning” numbers from the previous update of the SELECT trial in August that sent the value of the Danish pharma soaring and sparked a stampede from people to get hold of the drug.

Novo Nordisk to release clinical update on star drug Wegovy

Novo Nordisk delivered sizzling Q3 growth, thanks mainly to soaring sales for Ozempic. However, Eli Lilly's Q3 results looked even better than Novo Nordisk's.

Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?

Danish pharma titan Novo Nordisk released its latest financial report Thursday morning. For the first nine months of 2023, the company posted double-digit percentage sales growth over the prior-year period.

Why Novo Nordisk Stock Is Surging Higher Today

The remarks come as U.S. health insurers balk at the extreme cost of Wegovy and other obesity drugs and drop them from their plans.

Novo Nordisk says 80% of insured U.S. patients taking Wegovy pay less than $25 a month

Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years - limited only by their availability.

Novo Nordisk, Lilly see insatiable demand for weight-loss drugs

Novo Nordisk A/S (NVO) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Daniel Bohsen - Head of Investor Relations Lars Fruergaard Jorgensen - President and Chief Executive Officer Camilla Sylvest - Executive Vice President, Commercial Strategy and Corporate Affairs Doug Langa - Executive Vice President, North America Operations Martin Holst Lange - Executive Vice President, Development Karsten Munk Knudsen - Executive Vice President and Chief Financial Officer Conference Call Participants Michael Nedelcovych - TD Cowen Richard Parkes - BNP Paribas Seamus Fernandez - Guggenheim Securities Peter Verdult - Citigroup Mark Purcell - Morgan Stanley Emily Field - Barclays Simon Baker - Redburn Naresh Chouhan - Intron Health Florent Cespedes - Societe Generale Richard Vosser - JPMorgan Peter Welford - Jefferies Mattias Haggblom - Handelsbanken Emmanuel Papadakis - Deutsche Bank Michael Novod - Nordea Operator Good day and thank you for standing by. Welcome to the Q3 2023 Novo Nordisk A/S Earnings Conference Call.

Novo Nordisk A/S (NVO) Q3 2023 Earnings Call Transcript

Eli Lilly, which makes Mounjaro, and Denmark's Novo Nordisk, which makes Ozempic and Wegovy, are struggling to meet skyrocketing demand for their medications.

Obesity Drug Demand Outstrips Supply

The majority of U.S. patients with health insurance coverage taking Novo Nordisk's powerful weight-loss drug Wegovy are paying less than $25 per month, a senior executive said on Thursday.

Novo Nordisk: 80% of U.S. Wegovy patients with insurance paying less than $25/month

Novo Nordisk (NVO) reports encouraging third-quarter results, beating both earnings and sales estimates, driven by strong sales of diabetes and obesity care products. Management raises 2023 guidance.

Novo Nordisk (NVO) Q3 Earnings and Sales Beat, 2023 View Up

Novo Nordisk said its blockbuster weight-loss drug Wegovy could receive expanded approval from the U.S. Food and Drug Administration within six months.

News for Novo Nordisk Stock (NVO)